Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

New Life For Aveo’s Cancer Candidate

by Rick Mullin
November 17, 2014 | A version of this story appeared in Volume 92, Issue 46

Months after losing Astellas Pharma as a partner to develop tivozanib, Aveo Oncology has signed a licensing agreement with Ophthotech, a specialist in age-related macular degeneration, to study the small molecule as a treatment for nononcological diseases of the eye. Ophthotech will pay Aveo $500,000 to investigate tivozanib, a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor, and could make up to $8 million in milestone payments if it continues developing the drug candidate. Astellas dropped out of the $125 million agreement to develop tivozanib for cancer in January.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.